FQ
VYGR icon

First Quadrant’s Voyager Therapeutics VYGR Stock Holding History

First Quadrant’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,870
Closed -$138K – 692
2019
Q4 		$138K Sell
9,870
-3,562
-27% -$51.8K 0.01% 444
2019
Q3 		$231K Buy
13,432
+10,264
+324% +$215K 0.02% 403
2019
Q2 		$86K Buy
+3,168
New +$72.5K 0.01% 599

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

First Quadrant's VYGR Position: Q1 2020 in Review

First Quadrant sold out of Voyager Therapeutics (VYGR) in Q1 2020, closing a stake of 9,870 shares — an estimated $138K sold.

First Quadrant first reported a position in VYGR in Q2 2019 and held it in 3 quarters. The position peaked at $231K in Q3 2019. 121 funds tracked by Wall St. Rank hold VYGR as of Q1 2020.

  • First Quadrant reported no remaining Voyager Therapeutics position as of Q1 2020 after selling out during the quarter.
  • First Quadrant sold 9,870 Voyager Therapeutics shares in Q1 2020, an estimated $138K.
  • First Quadrant first reported a position in Voyager Therapeutics in Q2 2019 and held it in 3 quarters.
  • First Quadrant's Voyager Therapeutics position peaked at $231K in Q3 2019.
  • 121 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2020.

Based on First Quadrant's 13F filing for Q1 2020, filed 5 May 2020.